Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/57801
Tipo de documento
Trabalhos apresentados em eventosDireito Autoral
Acesso aberto
Coleções
Metadata
Mostrar registro completo
ADVERSE DRUG REACTIONS AFTER THE USE OF BENZNIDAZOLE IN BOLIVIAN PATIENTS WITH CHAGAS DISEASE
Autor(es)
Afiliação
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Médecins Sans Frontières. Operational Center. Barcelona (OCBA), Spain.
Médecins Sans Frontières. Operational Center. Barcelona (OCBA), Spain.
Médecins Sans Frontières. BRAMU (Brazilian Medical Unit). Médicos Sem Fronteiras. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Médecins Sans Frontières. Operational Center. Barcelona (OCBA), Spain.
Médecins Sans Frontières. Operational Center. Barcelona (OCBA), Spain.
Médecins Sans Frontières. BRAMU (Brazilian Medical Unit). Médicos Sem Fronteiras. Rio de Janeiro, RJ, Brazil.
Resumo em Inglês
Chagas disease remains an important problem in the world and there is an estimate of more than 10 million infected people worldwide. Benznidazole (BZN) is the main drug used for etiologic treatment of this disease. However, about 17 to 31% of patients discontinued the BZN treatment. The aim of the present study was to understand the predictors of BZN treatment discontinuation over time.
Female sex, older patients, those who lived in urban areas, patients who had had moderate or severe ADRs and those who had had skin disorders had a higher risk for BZN treatment discontinuation. For these patients, a close follow-up should be carried out, at regular intervals of at least once a week to monitor BZN treatment. Impact of study: The results of this study may help to identify patients of high risk for BZN treatment discontinuation. Also, these results suggest that a close follow-up by health professionals could be necessary in order to improve adherence and early detection of adverse drug reactions.
Compartilhar